ライフサイエンスコーパス: inhaled glucocorticoid

1 at was inadequately controlled with low-dose inhaled glucocorticoids.

2 mine changes in lung function in response to inhaled glucocorticoids.

3 rmacogenetic determinants of the response to inhaled glucocorticoids.

4 uncontrolled disease despite treatment with inhaled glucocorticoids.

5 ng beta-agonists and medium-to-high doses of inhaled glucocorticoids.

6 despite the receipt of medium- or high-dose inhaled glucocorticoids.

7 okers, 42% used bronchodilators and 23% used inhaled glucocorticoids.

8 Early intervention with inhaled glucocorticoids achieves symptom control but doe

9 ents whose asthma is poorly controlled by an inhaled glucocorticoid alone.

10 or response to an increase in the dose of an inhaled glucocorticoid and almost half had a superior re

11 h moderate-to-severe asthma, provision of an inhaled glucocorticoid and one-time instruction on its u

12 sociation of single therapy with systemic or inhaled glucocorticoids and improved outcomes in either

13 thma and elevated eosinophil levels who used inhaled glucocorticoids and LABAs, dupilumab therapy, as

14 poorly controlled asthma despite the use of inhaled glucocorticoids and LABAs, the addition of tiotr

15 912 patients with asthma who were receiving inhaled glucocorticoids and LABAs, we compared the effec

16 t airflow obstruction despite treatment with inhaled glucocorticoids and long-acting beta-agonists (L

17 omalizumab despite reductions in the use of inhaled glucocorticoids and long-acting beta-agonists.

18 we examined the relation between the dose of inhaled glucocorticoids and the rate of bone loss in pre

19 ons was similar among those who discontinued inhaled glucocorticoids and those who continued glucocor

20 Inhaled glucocorticoids are not as effective as systemic

21 Daily inhaled glucocorticoids are recommended for young childr

22 Although inhaled glucocorticoids are the mainstays of asthma trea

23 Inhaled glucocorticoids are the most commonly used medic

24 Inhaled glucocorticoids are the preferred long-term cont

25 s compared with a doubling of the dose of an inhaled glucocorticoid, as assessed by measuring the mor

26 tive pulmonary disease but not asthma) to an inhaled glucocorticoid, as compared with a doubling of t

27 oderate or severe exacerbations while taking inhaled glucocorticoid-based triple maintenance therapy.

28 Inhaled glucocorticoids can also improve airflow and can

29 moderate-to-severe asthma who were receiving inhaled glucocorticoid-containing maintenance therapies,

30 re asthma who were receiving a wide range of inhaled glucocorticoid-containing maintenance therapies.

31 , data are reassuring, supporting the use of inhaled glucocorticoids during pregnancy.

32 LABAs at week 4 and to taper and discontinue inhaled glucocorticoids during weeks 6 through 9.

33 ily or the LABA salmeterol (50 mug) plus the inhaled glucocorticoid fluticasone (500 mug) twice daily

34 y), salmeterol (50 mug twice daily), and the inhaled glucocorticoid fluticasone propionate (500 mug t

35 ed the addition of a LABA (salmeterol) to an inhaled glucocorticoid (fluticasone propionate), a step-

36 g the LABA salmeterol in combination with an inhaled glucocorticoid, fluticasone propionate.

37 We estimated the associations between use of inhaled glucocorticoids for asthma treatment during preg

38 The use of inhaled glucocorticoids for persistent asthma causes a t

39 While inhaled glucocorticoids have not consistently been shown

40 opium Bromide as an Alternative to Increased Inhaled Glucocorticoid in Patients Inadequately Controll

41 A larger daily dose of inhaled glucocorticoid in the first 2 years was associat

42 However, the benefit of inhaled glucocorticoids in addition to two long-acting b

43 ed significantly to our current knowledge of inhaled glucocorticoids in childhood asthma.

44 Treatment with inhaled glucocorticoids in combination with long-acting

45 th substantial decrements in the response to inhaled glucocorticoids in patients with asthma.

46 n attained height associated with the use of inhaled glucocorticoids in prepubertal children persiste

47 The effectiveness of inhaled glucocorticoids in shortening the time to sympto

48 ndicate reduced lung function in response to inhaled glucocorticoids in subjects with the variant all

49 Inhaled glucocorticoids, in addition, might reduce exace

50 height 1 to 4 years after the initiation of inhaled glucocorticoids is thought not to decrease attai

51 Inhaled glucocorticoids lead to a dose-related loss of b

52 edicted value and were taking a mean dose of inhaled glucocorticoids of 580 mug per day; 80% were als

53 The effects of inhaled glucocorticoids on outcomes in these infants are

54 er a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antag

55 2)-agonist (SABA) with or without a low-dose inhaled glucocorticoid or leukotriene-receptor antagonis

56 t least 3% who used medium-dose to high-dose inhaled glucocorticoids plus long-acting beta-agonists (

57 lts with moderate-to-severe asthma receiving inhaled glucocorticoids plus long-acting beta-agonists (

58 compared with a doubling of the dose of the inhaled glucocorticoid (primary superiority comparison)

59 Whether long-term therapy with inhaled glucocorticoids reduces bone mass, as oral gluco

60 enotype accounting for about 6.6% of overall inhaled glucocorticoid response variability.

61 use a patient-activated, reliever-triggered inhaled glucocorticoid strategy (beclomethasone dipropio

62 ry with persistent asthma who required daily inhaled glucocorticoid therapy and 1988 matched controls

63 t of BHR confirmed the beneficial effects of inhaled glucocorticoid therapy and allergen avoidance on

64 Although the Expert Panel had recommended inhaled glucocorticoid therapy as the preferred long-ter

65 The safety and efficacy of inhaled glucocorticoid therapy for asthma stimulated its

66 Lastly, the safety of inhaled glucocorticoid therapy was also evaluated in pre

67 Inhaled glucocorticoid therapy was associated with a dos

68 ies were published that investigated whether inhaled glucocorticoid therapy, if started soon after th

69 d less glucocorticoid responsiveness despite inhaled glucocorticoid therapy.

70 hma that was inadequately controlled despite inhaled glucocorticoid therapy.

71 ng beta-agonists and medium-to-high doses of inhaled glucocorticoids, those who received tezepelumab

72 persistent asthma to receive mometasone (an inhaled glucocorticoid), tiotropium (a long-acting musca

73 When added to an inhaled glucocorticoid, tiotropium improved symptoms and

74 cal interest was the comparative efficacy of inhaled glucocorticoid to systemic glucocorticoids in th

75 used on the comparative clinical efficacy of inhaled glucocorticoids to leukotriene receptor antagoni

76 inophilic inflammation despite high doses of inhaled glucocorticoids to one of three study groups.

77 We measured inhaled glucocorticoid use by means of monthly diaries,

78 The increased dose of inhaled glucocorticoids was associated with a decrease i

79 zation, LABA was discontinued at week 4, and inhaled glucocorticoids were tapered over weeks 6 throug

80 th fewer asthma exacerbations when LABAs and inhaled glucocorticoids were withdrawn, with improved lu

81 r a clinically directive trial to compare an inhaled glucocorticoid with other treatments in patients

82 It is unknown whether the concomitant use of inhaled glucocorticoids with LABAs mitigates those risks

83 despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocortic

84 ested the hypothesis that early therapy with inhaled glucocorticoids would decrease the frequency of